Schulkens Julie E M, van Alphen Sebastiaan P J, Stas Lara, Louter Mark A, Verhey Frans R J, Sobczak Sjacko
Alzheimer Centrum Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNs), Maastricht University, Maastricht, The Netherlands.
Clinical Center of Excellence for Older Adults with Personality Disorders, Mondriaan Mental Health Hospital, Mondriaan Ouderenzorg, Kloosterkensweg 10, 6419 PJ, Heerlen-Maastricht, The Netherlands.
Drugs Aging. 2025 Sep 2. doi: 10.1007/s40266-025-01244-y.
Medication use is increasing in psychiatric populations, particularly those with personality disorders (PDs). Older adults with PDs are at higher risk for adverse drug reactions (ADRs), which may interfere with daily functioning.
This study aimed to describe medication use and health-related quality of life (HR-QOL) in older adults with PDs compared with control groups and to evaluate predictors of medication use and HR-QOL.
The PhArmacotherapy aND pOlypharmacy in oldeR Adults (PANDORA) study is a Dutch multicenter cross-sectional study including 77 older adults with PDs (OA-PD), 54 younger to middle-aged adults with PDs (A-PD), and 88 healthy older adults (OA-H). Medication use was assessed via participant questionnaires and verified against electronic health records for patients. HR-QOL was measured using the EQ-5D-3L (visual analog scale [VAS] and utility score). Statistical analyses were performed with general linear models.
Polypharmacy (≥ 5 medications daily) was present in 55.8% of the OA-PD group. OA-PD used more psychotropic and somatic medications than OA-H (b = - 1.555, p < 0.001 and b = - 1.341, p < 0.001, respectively) and A-PD (b = - 0.753, p < 0.001 and b = - 2.128, p < 0.001, respectively). Medication use was predicted by the number of psychiatric and somatic diagnoses. OA-PD reported lower EQ-VAS (b = 20.659, p < 0.001) and lower EQ-utility scores (b = 0.351, p < 0.001) compared with OA-H. ADRs, rather than the number of medications, significantly predicted HR-QOL (p < 0.001).
Both somatic and psychotropic medication use is highly prevalent in OA-PD. OA-PD report lower HR-QOL compared with OA-H, in which ADRs may be a mediating factor. These findings underline the importance of regular medication reviews in older adults with PDs. Future research should investigate longitudinally the effect of deprescribing on HR-QOL in this population.
精神疾病患者,尤其是人格障碍(PD)患者的药物使用正在增加。患有PD的老年人发生药物不良反应(ADR)的风险更高,这可能会干扰日常功能。
本研究旨在描述与对照组相比,患有PD的老年人的药物使用情况和健康相关生活质量(HR-QOL),并评估药物使用和HR-QOL的预测因素。
老年成人药物治疗与多药联用(PANDORA)研究是一项荷兰多中心横断面研究,包括77名患有PD的老年人(OA-PD)、54名年龄较小至中年的PD患者(A-PD)和88名健康老年人(OA-H)。通过参与者问卷评估药物使用情况,并对照患者的电子健康记录进行核实。使用EQ-5D-3L(视觉模拟量表[VAS]和效用评分)测量HR-QOL。采用一般线性模型进行统计分析。
OA-PD组中55.8%的患者存在多药联用(每天≥5种药物)。与OA-H相比,OA-PD使用的精神药物和躯体药物更多(分别为b=-1.555,p<0.001和b=-1.341,p<0.001),与A-PD相比也是如此(分别为b=-0.753,p<0.001和b=-2.128,p<0.001)。药物使用情况由精神和躯体诊断的数量预测。与OA-H相比,OA-PD的EQ-VAS较低(b=20.659,p<0.001),EQ-效用评分也较低(b=0.351,p<0.001)。ADR而非药物数量显著预测HR-QOL(p<0.001)。
OA-PD中躯体药物和精神药物的使用都非常普遍。与OA-H相比,OA-PD的HR-QOL较低,其中ADR可能是一个中介因素。这些发现强调了对患有PD的老年人进行定期药物审查的重要性。未来的研究应纵向调查减药对该人群HR-QOL的影响。